SELLAS Q1 Loss Beats, Shares Up 20%

SELLAS reported Q1 adjusted loss of $0.05 per share, beating $0.07 estimate, while net loss widened to $8.4 million.
Shares surged 20.4% in after‑hours trading as the company disclosed 78 events in the REGAL Phase 3 AML trial, nearing the 80‑event trigger.
Cash stood at $107.1 million with $7.5 million from Q2 warrant exercises; an ATM facility with TD Cowen allows up to $150 million.
The company is dosing 80 patients in a Phase 2 SLS009 trial, expecting topline data in Q4 2026.